BNET Industries
GlaxoSmithKline Plc. is in the Pharma Industry
Latest News and Analysis
Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
Ohad Hammer submits: This article will discuss the development of Poniard’s lead drug, picoplatin, for the treatment of small cell lung cancer [SCLC]. A General introduction for picoplatin can be found in the first part of this article. by Ohad Hammer
What's Happening in Research and Development?
Joe Ponzio submits: Today's research and development [R&D] is tomorrow's new product or process. The other day we (or more specifically, Phil Fisher) asked, "Does the management have a determination to continue to develop products or processes that will still further increase total sales potentials when the growth potentials...
In Tech We Trust - Fast Money Recap (6/20/08)
Recap of Fast Money, Friday June 20. Dow Falls Below 12,000 by SA Editor Joan Wickham
FDA Stings Pharma, Big and Small
Michael Steinberg submits: The first shock came after Merck MRK and Schering-Plough’s SGP Vytorin ENHANCE study. Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval. Genzyme GENZ and Isis ISIS received the first blow. Isis’ cholesterol drug Mipomersen would have to undergo an outcomes study...
Britain Picks Glaxo Cervical Cancer Vaccine
LONDON (Reuters UK) - The Department of Health has picked GlaxoSmithKline's GSK cervical cancer vaccine Cervarix over Merck's MRK Gardasil for its immunisation programme, Glaxo said on Wednesday. The programme aims to protect against the two types of human papilloma virus responsible for about 70...
Glaxosmithkline's Weight-Loss Drug Disappoints as Expected
Derek Lowe submits: About a year ago, I wrote about Glaxosmithkline's GSK attempt to sell the lipase inhibitor orlistat over the counter as Alli: "So my forecast for Alli is strong sales - for a while. Then it takes a dive, never to scale those heights again, as...
Pfizer May Make Counter Bid For Ranbaxy
MUMBAI (Reuters UK) - Pfizer PFE may bid for Ranbaxy Laboratories RANB, countering a $4.6 billion (2.4 billion pounds) offer by Japan's Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper said. Pfizer, the world's largest drug maker, may bid for the...
GlaxoSmithKline's Cutbacks Should Come as No Surprise
Derek Lowe submits: Well, this is turning into GlaxoSmithKline GSK week around here, but with good reason. I’ve had a lot of mail from people who have been affected by this week’s cutbacks, and others who left the company before the latest round. And that leads to these thoughts...
Glaxo Axes 350 Research Jobs
By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK is axing around 350 jobs, or 2 percent of its global research workforce, as part of a restructuring programme, the world's second biggest drugmaker said on Wednesday. The cuts add to the growing tally of positions lost...
Glaxo Axes 350 Jobs in Overhaul of Drug Research
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc GSK is axing around 350 jobs in research and development as part of an ongoing restructuring program, Europe's biggest drugmaker said on Wednesday. The cuts add to the growing tally of positions lost in a...
GlaxoSmithKline Slashes Research Staff
Derek Lowe submits: Update: GSK is indeed wielding the ax Tuesday and Wednesday. I'm hearing that the smallest cuts are around 40% of the entire research staff at the various sites. This is big, and it's bad... GlaxoSmithKline GSK has been going through some sort of mid-life crisis recently....
Big Pharma in Effort to Stimulate Innovation
Eben Tessari submits: GSK to shake-up research strategies Financial Times UCSF, Pfizer sign collaborative research deal San Fransisco Chronicle Both Via Pharmalot by Eben Tessari
ADA's 68th Scientific Sessions: A New Look at Insulin Therapy
R.J Steffens submits: The American Diabetes Association's 68th Scientific Sessions kicked off in San Francisco on June 6th and ends June 10th. Large pharma dominates the exhibition and use the venue to present their latest study results in an effort to orientate health care professionals on the products they may...
GlaxoSmithKline Q3 2007 Earnings Call Transcript
GlaxoSmithKline Q3 2007 Earnings Call Transcript
GlaxoSmithKline Q2 2007 Earnings Call Transcript
GlaxoSmithKline Q2 2007 Earnings Call Transcript
GlaxoSmithKline Q2 2007 Earnings Call Transcript
GlaxoSmithKline Q2 2007 Earnings Call Transcript
GlaxoSmithKline: GlaxoSmithKline Consumer Healthcare Helps Smokers Quit With ASP.NET, C#, Commerce Server 2002 and the .NET Framework
GlaxoSmithKline Consumer Healthcare is the over-the-counter business unit of GSK, and shares the GSK corporate mission to improve the quality of human life. It wanted to redesign and re-architect its family of smoking cessation web sites, in order to extend its ability to support smokers throughout their stages of quitting,...
Additional Resources
A Competitor Analysis of the Antihypertensives Market Including Detailed Market Information and Major Companies Active in the Industry
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/1d8ee0/competitor_analysi) has announced the addition of the "Competitor Analysis: Antihypertensives" report to their offering. The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension...
FDA Approves KINRIX™ - New Combination Vaccine for Children
- New option could mean fewer shots for 4 to 6 year-olds in the U.S. - PHILADELPHIA, June 24 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that the U.S. Food and Drug Administration FDA has approved KINRIXTM [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus...
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...
- Next »
- page 1 of 308
- « Previous
Sort byClose
GlaxoSmithKline Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
